Potential of the pharmacological inhibition of CCL2-CCR2 axis via targeting FROUNT to prevent the initiation and the progression of intracranial aneurysms in rats
Journal of Neuropathology & Experimental Neurology · 2025
DOI: 10.1093/jnen/nlae115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2025. Verfasst von Isao Ono und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology, Research Institute, National Cerebral and Cardiovascular Center, Osaka, Japan. Hauptthemen laut MEDLINE: Receptors, CCR2, Chemokine CCL2, Intracranial Aneurysm, Disulfiram. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Core Research for Evolutional Science and Technology, Japan Agency for Medical Research and Development, AMED.
Abstract (Originalsprache)
Intracranial aneurysms (IAs) affect 1%-5% of the public and are a major cause of subarachnoid hemorrhage. Currently, there is no medical treatment to prevent the progression or rupture of IAs. Recent studies have defined IA as a chronic inflammatory disease in which macrophages infiltrate intracranial arteries via the CCL2-CCR2 axis. The chemokine signal regulator FROUNT mediates this axis, and it can be inhibited by the anti-alcoholism drug disulfiram. Therefore, inhibition of macrophage infiltration by interfering with FROUNT using disulfiram may represent a strategy to prevent exacerbation of IAs. Here, effects of disulfiram were investigated in vitro and in an animal model of IAs. FROUNT expression was observed on infiltrated macrophages both in human IAs and in the rat IA model by immunohistochemistry. In vitro treatment with disulfiram suppressed CCL2-mediated migration of cultured rat macrophages in a transwell system. Disulfiram administered in a rat model of IAs inhibited both the initiation and the enlargement of IAs in a dose-dependent manner; this was accompanied by suppression of macrophage infiltration. These results suggest that pharmacological inhibition of the CCL2-CCR2-FROUNT signaling cascade could be a treatment of patients with IAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pharmacology, Research Institute, National Cerebral and Cardiovascular Center, Osaka, Japan.
- Core Research for Evolutional Science and Technology (CREST) from Japan Agency for Medical Research and Development (AMED), National Cerebral and Cardiovascular Center, Osaka, Japan.
- Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Pharmacology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Neurosurgery, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan.
- Department of Neurosurgery, St Luke's International Hospital, Tokyo, Japan.
ORCID-Profile: Yoshiki Arakawa
Förderung
- Core Research for Evolutional Science and Technology
- Japan Agency for Medical Research and Development
- AMED
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Grant-in-Aid for Scientific Research
Zitieren
APA
Ono, I., Itani, M., Okada, A., Kawashima, A., Toda, E., Arakawa, Y., Terashima, Y., & Aoki, T. (2025). Potential of the pharmacological inhibition of CCL2-CCR2 axis via targeting FROUNT to prevent the initiation and the progression of intracranial aneurysms in rats. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlae115
Vancouver
Ono I, Itani M, Okada A, Kawashima A, Toda E, Arakawa Y, et al. Potential of the pharmacological inhibition of CCL2-CCR2 axis via targeting FROUNT to prevent the initiation and the progression of intracranial aneurysms in rats. Journal of Neuropathology & Experimental Neurology. 2025. doi:10.1093/jnen/nlae115
BibTeX
@article{Ono2025,
author = {Ono, Isao and Itani, Masahiko and Okada, Akihiro and Kawashima, Akitsugu and Toda, Etsuko and Arakawa, Yoshiki and Terashima, Yuya and Aoki, Tomohiro},
title = {Potential of the pharmacological inhibition of CCL2-CCR2 axis via targeting FROUNT to prevent the initiation and the progression of intracranial aneurysms in rats},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2025},
doi = {10.1093/jnen/nlae115}
}
EUVIMED